Regeneron Pharmaceuticals Stock Price

-12.45 (-2.0%)
Upgrade to Real-Time
Afterhours (Closed)
Best deals to access real time data!
Big Cap Pro
Monthly Subscription
for only
Small Cap Pro
Monthly Subscription
for only
DDE w/Realtime (Monthly)
Monthly Subscription
for only
VAT not included
Company Name Stock Ticker Symbol Market Type
Regeneron Pharmaceuticals Inc REGN NASDAQ Common Stock
  Price Change Change Percent Stock Price Low Price High Price Open Price Close Price Last Traded
13.28 2.18% 622.45 608.76 630.76 610.50 609.17 20:00:00
Bid Price Ask Price Spread Spread % News
607.30 613.89 6.59 1.07% 2 3
Stock Trades Traded Volume VWAP Dollar Volume Average Volume 52 Week Range
22,710 802,497 $ 623.27 $ 500,175,427 1,756,940 271.37 - 646.33
Last Trade Time Type Quantity Stock Price Currency
19:59:07 2 $ 610.00 USD

Regeneron Pharmaceuticals Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
$ 63.86B 102.60M 100.79M $ 7.86B $ 2.26B 18.45 31.20
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- $ - 0.00% - -

more financials information »

Regeneron Pharmaceuticals News

Loading Messages....

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....

No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts

Historical REGN Price Data

Period † Open High Low VWAP Avg. Daily Vol Change %
1 Week605.14630.76601.02614.47872,31217.312.86%
1 Month596.99646.33575.89610.541,024,28125.464.26%
3 Months510.10646.33500.87576.551,368,928112.3522.03%
6 Months378.00646.33328.125502.671,299,048244.4564.67%
1 Year319.69646.33271.37436.281,009,274302.7694.7%
3 Years494.20646.33271.37399.36859,396128.2525.95%
5 Years509.50646.33271.37410.93847,679112.9522.17%

Regeneron Pharmaceuticals Description

Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has six marketed products: Eylea, approved for wet age-related macular degeneration and other eye diseases; Praluent for LDL cholesterol lowering; Zaltrap in colorectal cancer; Dupixent in atopic dermatitis, asthma, and nasal polyposis; Libtayo in cutaneous squamous cell carcinoma; Arcalyst in CAPS; and Kevzara in rheumatoid arthritis. Regeneron is also developing monoclonal antibodies with Sanofi in immunology and cancer.

Your Recent History
Gulf Keyst..
FTSE 100
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.